Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-788-6 | CAS number: 110-65-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Non-GLP, guideline-equivalent study
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 992
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- yes
- Remarks:
- some clinical chemistry parameters and pathology parameters
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- But-2-yne-1,4-diol
- EC Number:
- 203-788-6
- EC Name:
- But-2-yne-1,4-diol
- Cas Number:
- 110-65-6
- Molecular formula:
- C4H6O2
- IUPAC Name:
- but-2-yne-1,4-diol
- Details on test material:
- Purity of test substance was approximately 99%.
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Wistar Imp:DAK
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Test animals were 6-8 weeks old at the start of dosing, with initial body weights of 188 +/- 20g (males) and 145 +/- 15g (females). Animals were randomly assigned either to control or test groups. They were kept in a room equipped with automatic light-cylcle timers and were housed in polypropylene bedding, four animals in each. Relative humidity and temperature were maintained at 40-60% and 20-21C, respectively. Food (Murigan pelled rodent chow, Wytwornia Pasz, Motycz, Poland) and tap water were provided ad libitum.
Administration / exposure
- Route of administration:
- oral: gavage
- Details on oral exposure:
- Distilled or diluted test material was administered with a syringe and a stainless-steel ball-tipped feeding needle in a volume of 1 ml/kg via oral gavage. Treated animals received the test material at doses of 1 mg/kg (low dose), 10 mg/kg (mid-dose), and 50 mg/kg (high dose). Control animals recieved equal volume of distilled water.
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- daily, reported as "consecutive days" and interpreted as 7 days per week for 4 weeks.
Doses / concentrations
- Remarks:
- Doses / Concentrations:
1; 10; 50 mg/kg
Basis:
- No. of animals per sex per dose:
- 8 males and 8 females per dose
- Control animals:
- yes
- Details on study design:
- Post-exposure period: none
- Positive control:
- none
Examinations
- Observations and examinations performed and frequency:
- Animals were observed daily for signs of overt toxicity. Body weights were recorded before the first dosing and twice a week thereafter during the test period. Food consumption was measured weekly.
- Sacrifice and pathology:
- At the end of the treatment period, rats were fasted overnight. Just before necropsy, blood samples were drawn from the tail vein for haemotological measurements (see Table 1). Animals were subsequently anesthetized with ethyl ether, sacrificed by exsanguination from the abdominal aorta and subjected to gross necropsy. Blood samples were collected for clinical chemistry measurements (see Table 2). The tissue and organs listed in Table 3 were fixed in 10% neutral-buffered formalin, processed and embedded in paraffin wax, sectioned, stained with hemotoxylin and eosin and evaluated microscopically. Evaluation of rats which died during the study was performed as described above except that the organs were not weighed and blood samples were not taken.
- Statistics:
- Except for body weight data, the differences between experimental and control groups were analysed using the following tests: Bartlett's test of homogeneity of variance was used at the P < 0.01 level. When variances were not significantly different, groups were compared with thte standard one-way variance (ANOVA). In the next step, Dunnet's test was used to determine which treatment groups differed from controls. In the absence of homogeneous variances, the Kruskal-Wallis test was used to assess differences and Dunn's summed rank test to determine which treatment group differed significantly from control. Body weight data were evaluated by analysis of covariance (ANCOVA), where day 1 was treated as a covariate, followed by Dunnett's test for comparison to controls. All these procedures were carried out with the TOXSTAT program.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- 3 of 8 males and 3 of 8 females rats died from the high dose group
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- 3 of 8 males and 3 of 8 females rats died from the high dose group
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Body weight gain was lower in males from the high dose group compared to controls
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- slightly reduced in males from high-dose group
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- See Table 4.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- See Table 5.
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Absolute liver weights in the high dose male and female animals were significantly higher than in the controls. When expressed on a relative basis, the liver weights of females in the mid-dose group and of both sexes in the high dose group were significa
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- hepatic and splenic lesions
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Congested internal organs, pulmonary oedema and severe changes in liver and kidneys.
- Histopathological findings: neoplastic:
- not specified
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 1 mg/kg bw/day (nominal)
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- clinical biochemistry
- haematology
- histopathology: non-neoplastic
- organ weights and organ / body weight ratios
- Dose descriptor:
- LOAEL
- Effect level:
- 10 mg/kg bw/day (nominal)
- Sex:
- male/female
- Basis for effect level:
- haematology
- histopathology: non-neoplastic
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Three male and three females in the highest group of doses died within the duration of the test. In the other experimental groups, there was no mortality. With the section of the animals, those that died in duration of the test had congested internal organs, pulmonary edemas and severe changes in liver and kidneys, which included diffuse hepatic parenchymal necrosis, accompanied by reactive mononuclear cells and granulocytes, fatty changes, as well as renal tubular degeneration and interstitial mononuclear cell infiltration in the kidney, (degeneration of the tubules among other things) were determined.
The body weight gain of the male animals in the highest group of doses was reduced, in the other groups of doses and with the female animals this effect was not significant. Food consumption was slightly reduced with the male rats in the highest group of doses. The absolute and relative liver weights and relative kidney weights of both sexes in the highest group of doses was significantly increased. The relative liver weight was increased with the female animals of the middle group of doses. The absolute kidney weights were increased in the female animals at the highest dose. The weights of spleen, suprarenal bodies and testicles were not changed.
Results of hematology and serum chemistry investigations are shown in Tables 4 and 5, respectively.
In the survivor animals in the high and middle doses, histopathological investigations showed dose-dependent liver damages and spleen changes. The authors state in summary that the notable features of the subacute poisoning are chronic liver inflammation and liver hypertrophy.
Table 4. Haematological Parameters
Parameter |
Control |
1 mg/kg |
10 mg/kg |
50 mg/kg |
RBC (x 106mm-3) males |
10.9±0.6 |
11.5±1.3 |
10.4±0.7 |
11.1±1 |
RBC (x 106mm-3) females |
11.1±1.0 |
10.9±0.9 |
10±0.8* |
8.8±1** |
Haematocrit (%) males |
52.0±1.7 |
51.6±1.4 |
51.9±1.2 |
50.6±2.3 |
Haematocrit (%) females |
47.9±1.8 |
49.7±1.5 |
48.0±1.9 |
42.6±3.4** |
Haemoglobin (g dl-1) males |
14.3±1.1 |
15.6±0.8 |
16.0±1.1 |
14.7±1.2 |
Haemoglobin (g dl-1) females |
13.5±0.7 |
13.6±1.2 |
13.5±0.4 |
12.3±0.6 |
Mean corpuscular haemoglobin (pg) males |
13.2±0.8 |
13.8±1.8 |
15.5±1.5 |
13.3±1.9 |
Mean corpuscular haemoglobin (pg) females |
12.2±0.9 |
12.5±1.6 |
13.6±1.3 |
14.1±2 |
Reticulocytes (‰) males |
5.0±2.9 |
5.5±2.0 |
5.4±1.4 |
12.4±2.9** |
Reticulocytes (‰) females |
5.0±2.0 |
7.5±1.5 |
4.9±0.8 |
10.0±3.7** |
WBC (x 106mm-3) males |
16.1±3.1 |
17.5±3.1 |
15.8±3.5 |
24.1±2.9** |
WBC (x 106mm-3) females |
13.7±4.5 |
13.6±1.8 |
10.2±3.0 |
23.6±6.9** |
Differential Neutrophils (x 106mm-3) males |
4.4±2.0 |
3.8±1.3 |
3.7±1.7 |
7.4±2.3* |
Differential Neutrophils (x 106mm-3) females |
3.3±1.4 |
2.2±0.9 |
2.3±0.8 |
8.4±5.6** |
Differential Lymphocytes (x 106mm-3) males |
11.5±2.4 |
13.1±2.5 |
11.2±2.6 |
15.8±3.5* |
Differential Lymphocytes (x 106mm-3) females |
9.7±3.6 |
11.2±1.8 |
7.1±1.9 |
14.8±3.6* |
* Significantly different from control (P < 0.05).
** Significantly different from control (P < 0.01).
Table 5. Serum Chemistry Parameters
Parameter |
Control |
1 mg/kg |
10 mg/kg |
50 mg/kg |
Alanine aminotransferase (U/l) males |
42.0±13.7 |
56.0±19.8 |
33.3±4.4 |
42.5±14.8 |
Alanine aminotransferase (U/l) females |
32.5±5.3 |
34.4±12.3 |
34.5±10.8 |
43.7±8.2 |
Sorbital dehydrogenase (U/l) males |
1.64±0.41 |
1.44±0.29 |
1.68±0.42 |
3.74±2.32** |
Sorbital dehydrogenase (U/l) females |
1.26±0.47 |
0.94±0.29 |
1.37±0.21 |
5.06±2.90** |
Total protein (g/dl) males |
6.16±0.28 |
6.38±0.19 |
6.14±0.41 |
6.56±0.27 |
Total protein (g/dl) females |
6.85±0.21 |
6.86±0.29 |
6.79±0.23 |
7.33±0.32* |
Albumin (g/dl) males |
3.16±0.29 |
3.26±0.16 |
3.28±0.14 |
3.31±0.22 |
Albumin (g/dl) females |
3.55±0.23 |
3.69±0.17 |
3.6±0.19 |
3.79±0.31 |
Glucose (mg/dl) males |
109±17 |
98±25 |
112±12 |
142±24* |
Glucose (mg/dl) females |
124±21 |
128±29 |
99±26 |
122±26 |
* Significantly different from control (P < 0.05).
** Significantly different from control (P < 0.01).
Applicant's summary and conclusion
- Executive summary:
2 -Butyne-1,4 -diol was given to male and female Wistar Imp:DAK rats by oral gavage for 28 consecutive days in daily doses of 1, 10, or 50 mg/kg/day. After 28 days all animals are necropsied. Blood samples were obtained and selected organs were weighed and prepared for histological examination. Treatment-related effects in the high-dose group consisted of: fatal cases in both sexes; decreased body weight gain in males; increase of absolute and/or relative weights of liver and kidneys in both sexes; depressed red blood cell count; haematocrit value and haemoglobin concentration in female rats ande elevated reticulocyte count and leukocyte count in both sexes; increased total serum protein content in females, elevated glucose concentration in males and higher activity of sorbital dehydrogenase in both sexes; and histopathological evidence of hepatotoxicity and nephrotoxicity in decedents, and hepatic and splenic changes in survivors. Minor hepatic, splenic, and erythrocyte changes were also found in some females given the middle dose. The dose of 1 mg/kg/day was considered to the NOAEL, and 10 mg/kg/day the LOAEL.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
